United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $511.97, for a total transaction of $4,863,715.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $166,105,082.71. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Trading Up 1.1%

Shares of NASDAQ UTHR opened at $518.53 on Wednesday. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The company has a 50 day simple moving average of $531.75 and a two-hundred day simple moving average of $538.30. The stock has a market cap of $22.24 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $6.41 EPS. Analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Institutional Trading of United Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 70 shares during the period. Jump Financial LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter worth about $277,000. Cerity Partners LLC boosted its stake in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia grew its position in shares of United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Finally, JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.